Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 0.03.

  • Northwest Biotherapeutics' Asset Utilization Ratio fell 4383.8% to 0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.03, marking a year-over-year decrease of 4383.8%. This contributed to the annual value of 0.05 for FY2024, which is 2244.72% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Asset Utilization Ratio stood at 0.03, which was down 4383.8% from 0.04 recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Asset Utilization Ratio high stood at 0.07 for Q3 2023, and its period low was 0.03 during Q1 2021.
  • Its 5-year average for Asset Utilization Ratio is 0.05, with a median of 0.05 in 2024.
  • In the last 5 years, Northwest Biotherapeutics' Asset Utilization Ratio plummeted by 8897.36% in 2021 and then soared by 10383.96% in 2023.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Asset Utilization Ratio stood at 0.03 in 2021, then skyrocketed by 83.45% to 0.05 in 2022, then increased by 20.72% to 0.07 in 2023, then fell by 24.25% to 0.05 in 2024, then crashed by 36.83% to 0.03 in 2025.
  • Its Asset Utilization Ratio stands at 0.03 for Q3 2025, versus 0.04 for Q2 2025 and 0.05 for Q1 2025.